Free Trial
NASDAQ:GLYC

GlycoMimetics (GLYC) Stock Price, News & Analysis

GlycoMimetics logo
$0.16 -0.01 (-6.63%)
Closing price 06/13/2025
Extended Trading
$0.16 0.00 (0.00%)
As of 06/13/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About GlycoMimetics Stock (NASDAQ:GLYC)

Key Stats

Today's Range
$0.15
$0.17
50-Day Range
$0.16
$27.47
52-Week Range
$14.06
$63.00
Volume
1.05 million shs
Average Volume
64,529 shs
Market Capitalization
$10.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Moderate Buy

Company Overview

GlycoMimetics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
24th Percentile Overall Score

GLYC MarketRank™: 

GlycoMimetics scored higher than 24% of companies evaluated by MarketBeat, and ranked 2488th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for GlycoMimetics are expected to remain at ($0.08) per share in the coming year.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of GlycoMimetics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of GlycoMimetics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    GlycoMimetics has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about GlycoMimetics' valuation and earnings.
  • Percentage of Shares Shorted

    2.90% of the float of GlycoMimetics has been sold short.
  • Short Interest Ratio / Days to Cover

    GlycoMimetics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GlycoMimetics has recently increased by 1.79%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    GlycoMimetics does not currently pay a dividend.

  • Dividend Growth

    GlycoMimetics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.90% of the float of GlycoMimetics has been sold short.
  • Short Interest Ratio / Days to Cover

    GlycoMimetics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GlycoMimetics has recently increased by 1.79%, indicating that investor sentiment is decreasing.
  • Search Interest

    1 people have searched for GLYC on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added GlycoMimetics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, GlycoMimetics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.70% of the stock of GlycoMimetics is held by insiders.

  • Percentage Held by Institutions

    75.19% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about GlycoMimetics' insider trading history.
Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

GLYC Stock News Headlines

Crescent Biopharma Inc.
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Headlines

GLYC Stock Analysis - Frequently Asked Questions

GlycoMimetics' stock was trading at $24.90 on January 1st, 2025. Since then, GLYC stock has decreased by 99.4% and is now trading at $0.1550.

GlycoMimetics, Inc. (NASDAQ:GLYC) announced its quarterly earnings data on Wednesday, May, 14th. The biotechnology company reported ($4.00) EPS for the quarter, beating analysts' consensus estimates of ($5.00) by $1.00.

Shares of GlycoMimetics reverse split before market open on Monday, June 16th 2025.The 1-100 reverse split was announced on Thursday, June 5th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that GlycoMimetics investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Bristol Myers Squibb (BMY), Meta Platforms (META), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

Last Earnings
5/14/2025
Today
7/03/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GLYC
Employees
50
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$37.88 million
Pretax Margin
-397,340.00%

Debt

Sales & Book Value

Annual Sales
$10 thousand
Price / Cash Flow
N/A
Book Value
$0.08 per share
Price / Book
1.94

Miscellaneous

Free Float
58,901,000
Market Cap
$10.00 million
Optionable
Optionable
Beta
1.62

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:GLYC) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners